Longeveron Inc. (LGVN) News

Longeveron Inc. (LGVN): $4.36

0.24 (+5.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LGVN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter LGVN News Items

LGVN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

LGVN News Highlights

  • LGVN's 30 day story count now stands at 4.
  • Over the past 13 days, the trend for LGVN's stories per day has been choppy and unclear. It has oscillated between 2 and 2.
  • The most mentioned tickers in articles about LGVN are GAME and MET.

Latest LGVN News From Around the Web

Below are the latest news stories about LONGEVERON INC that investors may wish to consider to help them evaluate LGVN as an investment opportunity.

LGVN: Longeveron Posts Positive Results for Life-Threatening Condition

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT LGVN (NASDAQ:LGVN) is a clinical stage biotech company that is using cutting edge cellular technology for various major medical conditions that we believe is undervalued by investors who are not appreciating the game-changing potential that the signature treatment, Lomecel-B, has to impact people’s lives. That belief was

Yahoo | January 19, 2023

Longeveron Announces Publication of Final Data from ELPIS I Trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome in Peer-Reviewed Journal

-- Full results published in European Heart Journal Open -- -- Study met primary safety endpoint -- -- All patients alive, transplant-free, and maintained expected rate of growth one year after treatment -- -- Data supports ongoing clinical development of Lomecel-BTM for HLHS, currently being evaluated in a Phase 2a trial -- MIAMI, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines

Yahoo | January 19, 2023

3 Penny Stocks That Could Rise 500% in 2023

Tilt the odds in your favor in 2023 with some of these high-potential penny stocks.

Thomas Yeung on InvestorPlace | January 13, 2023

UPDATE -- Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones

– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a corporate update highlighting the Company’s strategic priorities and anticipated milestones for 2023. “This past year Longeveron m

Yahoo | January 6, 2023

Longeveron Provides Corporate Update and Announces 2023 Strategic Priorities and Anticipated Milestones

– Expects to enroll first patient in Phase 2 clinical trial of Lomecel-B™ for Aging-Related Frailty in Japan in 1Q23 – – Extended cash runway into 2H24 – MIAMI, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a corporate update highlighting the Company’s strategic priorities and anticipated milestones for 2023. “This past year Longeveron m

Yahoo | January 6, 2023

Elon Musk Is a Genius Market Timer. That’s Bad News for Tesla (TSLA) Stock.

Elon Musk is great at timing the market.

Thomas Yeung on InvestorPlace | December 19, 2022

Longeveron to Participate in Upcoming 2022 Investor Conferences

MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that Company leadership will participate in three upcoming investor conferences.

GlobeNewswire | November 29, 2022

Longeveron (LGVN) Gets a Buy from Maxim Group

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Longeveron (LGVN - Research Report), with a price target of $14.00. The company's shares opened today at $4.09.According to TipRanks, Okunewitch is an analyst with an average return of -28.7% and a 20.69% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as TFF Pharmaceuticals, Gilead Sciences, and Kiora Pharmaceuticals.Currently, the analyst consensus on Longeveron is a Moderate Buy with an average price target of $14.00.See the top stocks recommended by analysts >>The company has a one-year high of $45.00 and a one-year low of $2.84.

Christine Brown on TipRanks | November 16, 2022

Longeveron Third Quarter 2022 Earnings: Revenues Beat Expectations, EPS Lags

Longeveron ( NASDAQ:LGVN ) Third Quarter 2022 Results Key Financial Results Net loss: US$5.24m (loss widened by 8.0...

Yahoo | November 16, 2022

Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results

— Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease — — Conference call scheduled for 8:30 a.m. ET today — MIAMI, Nov. 14, 2022 (GLOBE NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative […] The post Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2022 Financial Results appeared first on ForexTV .

ForexTV | November 14, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5669 seconds.